J&J reduce personal (USA): 900 personas

J&J joins New York-based Pfizer Inc., Merck & Co. of Whitehouse Station, New Jersey, and other drugmakers that have cut staff amid rising generic competition. Sales for the antipsychotic Risperdal, once J&J’s top-selling product, fell from $3.42 billion in 2007 to $2.21 billion last year as lower- cost rivals entered the market. Its third-biggest drug, migraine treatment Topamax, lost patent protection earlier this year.

“The health-care environment is changing and it behooves us to look at what is valued in that environment,” Russell(spokeswoman for the New Brunswick, New Jersey-based J&J) said. “It’s not simply about losing patents. It’s really about how you are going to develop a model that adds value” for doctors, patients and other “stakeholders,” she said.

Mas de Bloomberg...